Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RAPLON vs ALDOMET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
RAPLON (levosimendan) is a calcium sensitizer that increases myocardial contractility by sensitizing troponin C to calcium, and it also opens ATP-sensitive potassium channels, causing vasodilation.
Methyldopa is a centrally acting alpha-2 adrenergic agonist. Its active metabolite, alpha-methylnorepinephrine, stimulates presynaptic alpha-2 receptors in the central nervous system, reducing sympathetic outflow from the brainstem and decreasing peripheral vascular resistance, leading to lowered blood pressure.
Short-term treatment of acutely decompensated chronic heart failure (NYHA III-IV) in patients with low cardiac output refractory to standard therapy,Off-label: Management of low cardiac output syndrome after cardiac surgery,Off-label: Treatment of cardiogenic shock
Hypertension (first-line in pregnancy-induced hypertension),Off-label: treatment of hypertensive crises
0.2 mg/kg IV bolus over 30 seconds; may repeat once if necessary after 15 minutes.
250 mg orally twice daily, increased as needed every 2-3 days; usual maintenance 500 mg to 2 g/day in 2-4 divided doses; maximum 3 g/day.
Terminal elimination half-life is approximately 1.5-2.5 hours in patients with normal renal function; prolonged in renal impairment (up to 6-8 hours in end-stage renal disease).
1.5–2 hours (terminal elimination half-life); clinical context: Renal impairment prolongs half-life (up to 4–6 hours in severe impairment), necessitating dose adjustment.
Primarily metabolized by the liver via conjugation to a methyl ester, which is then further conjugated by glutathione-S-transferase. The active metabolite (OR-1896) has a long half-life.
Primarily hepatic metabolism via conjugation and O-methylation; also undergoes decarboxylation and deamination. Active metabolites include alpha-methyldopamine and alpha-methylnorepinephrine.
Primarily renal excretion of unchanged drug (approximately 80-90% of administered dose within 24 hours); minor biliary/fecal elimination (less than 10%).
Renal: ~70% as unchanged drug and metabolites (sulfate conjugate, O-methylated derivatives); fecal/biliary: ~20%; <5% removed by hemodialysis.
Approximately 30-40% bound to plasma proteins, primarily albumin.
~10-20% bound to plasma proteins (primarily albumin).
Volume of distribution is approximately 0.2-0.3 L/kg, indicating distribution primarily into extracellular fluid.
0.2–0.4 L/kg; clinical meaning: Moderate distribution, indicating limited extravascular penetration.
Intravenous: 100% (only route used clinically). Intramuscular: Not routinely used; bioavailability data limited.
Oral: ~50% (range 25-60%) due to first-pass metabolism; IV: 100%.
No dose adjustment required; RAPLON is not significantly renally eliminated.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: interval every 12-24 hours; GFR <10 m L/min: interval every 24-48 hours or 250 mg every 36-48 hours.
Child-Pugh A and B: no adjustment; Child-Pugh C: use with caution, consider reducing dose by 50% due to prolonged duration.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or reduce dose by 75%.
0.2 mg/kg IV bolus over 30 seconds; maximum single dose 10 mg; may repeat once after 15 minutes.
10 mg/kg/day orally in 2-4 divided doses, increased gradually; maximum 65 mg/kg/day or 3 g/day.
Use 0.15 mg/kg IV bolus over 30 seconds due to increased sensitivity and risk of prolonged neuromuscular blockade.
Initial dose 250 mg once or twice daily; increase slowly; monitor for hypotension, sedation, and bradycardia; avoid in patients with pre-existing bradycardia or heart block.
None
None
Hypotension; tachyarrhythmias; renal impairment; electrolyte disturbances (hypokalemia, hypomagnesemia) may increase risk of arrhythmias; monitoring of blood pressure, heart rate, and ECG required; not recommended in severe hepatic impairment.
Hepatic toxicity (fatal hepatic necrosis reported); hemolytic anemia (positive Coombs test common, may indicate hemolysis); sedation/drowsiness (impair mental alertness); orthostatic hypotension; caution in renal impairment (dose adjustment required); may cause positive direct Coombs test, which interferes with crossmatching; possible rebound hypertension upon abrupt discontinuation.
Hypersensitivity to levosimendan or any excipient; severe hypotension (systolic BP < 85 mm Hg); severe tachyarrhythmia; significant mechanical obstruction affecting ventricular filling or outflow; history of torsades de pointes; severe renal impairment (Cr Cl < 30 m L/min); severe hepatic impairment.
Active hepatic disease (acute hepatitis, cirrhosis); prior methyldopa-induced hepatic dysfunction; concurrent MAO inhibitor therapy; hypersensitivity to methyldopa; pheochromocytoma.
Grapefruit and grapefruit juice may increase the effects and prolong paralysis. Clarithromycin, itraconazole, and other CYP3A4 inhibitors can enhance duration. Avoid high-fat meals shortly before use as they may delay onset.
Avoid excessive sodium intake, as it can counteract the antihypertensive effect. No specific food interactions reported, but alcohol may potentiate hypotension and sedation. Iron supplements may reduce absorption of methyldopa; separate administration by at least 2 hours.
Pregnancy Category C. No adequate human studies. Trimester 1: Risk of fetal malformations cannot be ruled out; animal studies show decreased fetal weight at maternally toxic doses. Trimester 2-3: Potential for fetal respiratory depression or apnea when used near term; avoid during labor.
First trimester: No increased risk of major congenital malformations reported in human studies based on limited data. Second and third trimesters: No known teratogenicity; use for management of chronic hypertension in pregnancy is common, but consider potential for reduced placental perfusion if maternal blood pressure is excessively lowered.
Not recommended. No human data available on excretion into breast milk. M/P ratio unknown.
Methyldopa is excreted into breast milk in small amounts (M/P ratio approximately 0.2-0.5). At typical maternal doses, infant exposure is likely subtherapeutic and considered compatible with breastfeeding. Monitor infant for potential hypotension or sedation.
No dose adjustment required; however, increased clearance in late pregnancy may necessitate higher doses, but clinical significance unknown.
Pregnancy may increase volume of distribution and renal clearance, potentially reducing methyldopa plasma concentrations. Dose adjustments may be necessary to maintain blood pressure control; monitor and titrate based on maternal blood pressure response. Typical starting dose: 250 mg orally twice daily; maximum up to 3 g/day in divided doses, but lower doses are often effective.
RAPLON (rapacuronium) is a rapid-onset, short-duration nondepolarizing neuromuscular blocker. It produces paralysis within 60-90 seconds and lasts 15-20 minutes. Avoid in patients with significant hepatic or renal impairment. Use with caution in elderly and those with electrolyte imbalances. Reversal with neostigmine is effective but may require higher doses. Monitor for histamine release and bronchospasm, especially in asthmatics.
ALDOMET (methyldopa) is a centrally acting alpha-2 agonist used primarily for hypertension in pregnancy. Monitor for positive direct Coombs test, which can occur in up to 20% of patients on long-term therapy; this may interfere with cross-matching but rarely causes hemolysis. Hepatic adverse effects, including increased liver enzymes and rarely hepatitis, require monitoring. Sedation and dizziness are common initially; titrate dose slowly. Methyldopa may cause orthostatic hypotension; advise patients to rise slowly. A paradoxical pressor response may occur if given with MAO inhibitors.
This medication causes complete paralysis, including inability to breathe, so you will be on a breathing machine.,Tell your doctor if you have asthma, liver or kidney disease, or any allergies.,Inform your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.,You may experience temporary muscle weakness after the drug wears off.,Avoid grapefruit and grapefruit juice before and after procedure.,Report any difficulty breathing, rash, or itching immediately.
Take exactly as prescribed; do not skip doses or stop suddenly as this may cause rebound hypertension.,This medication may cause drowsiness, especially at start of therapy; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying positions to minimize dizziness or fainting.,Report any unexplained fever, fatigue, jaundice (yellowing of skin/eyes), or dark urine to your healthcare provider immediately, as these may indicate liver problems.,Notify your doctor if you experience persistent dry mouth, flu-like symptoms, or swelling in the legs.,Regular blood pressure monitoring is essential; keep a log of readings.,Avoid alcohol, as it can increase drowsiness and lower blood pressure further.,Inform all healthcare providers, including dentists, that you are taking this medication.,Do not take any other medications, including over-the-counter products, without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RAPLON vs ALDOMET, answered by our medical review team.
RAPLON is a Antihypertensive that works by RAPLON (levosimendan) is a calcium sensitizer that increases myocardial contractility by sensitizing troponin C to calcium, and it also opens ATP-sensitive potassium channels, causing vasodilation.. ALDOMET is a Central Alpha Agonist Antihypertensive that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist. Its active metabolite, alpha-methylnorepinephrine, stimulates presynaptic alpha-2 receptors in the central nervous system, reducing sympathetic outflow from the brainstem and decreasing peripheral vascular resistance, leading to lowered blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RAPLON and ALDOMET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RAPLON is: 0.2 mg/kg IV bolus over 30 seconds; may repeat once if necessary after 15 minutes.. The standard adult dose of ALDOMET is: 250 mg orally twice daily, increased as needed every 2-3 days; usual maintenance 500 mg to 2 g/day in 2-4 divided doses; maximum 3 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RAPLON and ALDOMET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RAPLON is classified as Category C. Pregnancy Category C. No adequate human studies. Trimester 1: Risk of fetal malformations cannot be ruled out; animal studies show decreased fetal weight at maternally toxic doses.. ALDOMET is classified as Category C. First trimester: No increased risk of major congenital malformations reported in human studies based on limited data. Second and third trimesters: No known teratogenicity; use for . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.